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Introduction: The Canadian Society of Nephrology (CSN) was established to promote the highest quality of care
for patients with renal diseases and to encourage research related to the kidney and its disorders. The CSN Clinical
Practice Guideline (CPG) Committee develops guidelines with clear recommendations to influence physicians’
practice and improve the health of patients with kidney disease in Canada.
Review: In this review we describe the CSN process in prioritizing CPGs topics. We document the CSN experience
using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. We then
detail the CSN process in developing de novo CPGs and in adapting existing CPGs and developing accompanying
commentaries. We also discuss challenges faced during this process and suggest solutions. Furthermore, we
summarize the CSN effort in disseminating and implementing their guidelines. Additionally, we describe recent
development and partnerships that allow evaluation of the effect of the CSN guidelines and commentaries.
Conclusion: The CSN follows a comprehensive process in identifying priority areas to be addressed in CPGs. In
2010, the CSN adopted GRADE, which enhanced the rigor and transparency of guideline development. This process
focuses on systematically identifying best available evidence and carefully assessing its quality, balancing benefits
and harms, considering patients’ and societies’ values and preferences, and when possible considering resource
implications. Recent partnership allows wider dissemination and implementation among end users and evaluation
of the effects of CPG and commentaries on the health of Canadians.
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CommentaryIntroduction: La mission de la Société canadienne de néphrologie (SCN) est de promouvoir des soins de grande
qualité aux patients atteints de maladies rénales et d’encourager la recherche en néphrologie. Le comité des guides
de pratique clinique (GPC) de la SCN a pour objectif le développement de lignes directrices comportant des
recommandations claires de façon à influencer la pratique médicale et d’améliorer le bien-être des patients atteints
de maladies rénales au Canada.
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Revue: Dans cette publication, nous décrivons l’approche utilisée par la SCN dans la priorisation des différents
sujets abordés dans les GPC. Nous abordons l’expérience de la SCN avec l’utilisation de l’approche GRADE (Grading
of Recommendations Assessment, Development, and Evaluation). Nous détaillons également le processus utilisé par la
SCN dans le développement de nouveaux GPC et dans la modification des GPC existants. Nous discutons des
difficultés rencontrées lors de ce processus tout en suggérant des solutions. Nous résumons les efforts encourus par
la SCN pour la diffusion et l’application des lignes directrices. Finalement, nous décrivons les récentes collaborations
de la SCN permettant l’évaluation de l’impact des lignes directrices de la SCN.
Conclusion: La SCN suit un processus rigoureux dans l’identification des priorités à aborder dans les GPC. Depuis
2010, la SCN a décidé d’adopter l’approche GRADE pour faire preuve de plus de rigueur et de transparence dans
l’élaboration de lignes directrices. Cette approche consiste à identifier toutes les évidences en étudiant leur qualité,
en mesurant les risques et les bénéfices, en considérant les valeurs et les préférences pour les patients ainsi que la
société et en tenant compte des ressources disponibles. Le partenariat permet une plus grande diffusion des
guides de pratique et une évaluation des effets des GPC sur la santé des canadiens.Introduction
The Canadian Society of Nephrology (CSN) mission in-
cludes promoting the highest quality of care for patients
with renal diseases and encouraging research related to
the kidney and its disorders. The Clinical Practice
Guidelines (CPG) Committee is one of five subcommit-
tees of the CSN, with a mandate to develop CPG with
clear recommendations for CSN members [1]. Broadly
speaking, CPGs are systematically developed statements
to assist practitioners and patients in reaching optimal
health care decisions. Their purpose is to “make explicit
recommendations with a definite intent to influence
clinical practice” [2]. Properly developed CPGs assimilate
and translate the abundance of evidence published on a
daily basis into recommendations. In doing so, CPGs
aim to reduce the use of unnecessary or harmful inter-
ventions, and facilitate the treatment of patients to
achieve maximum benefit and minimum harm at an ac-
ceptable cost. CPGs are not meant to replace, but rather
augment, sound medical decision making which takes
into account critical elements relevant to patient care in-
cluding patients’ values and preferences and clinician
experience.
The primary objective of the CSN CPG Committee is
to develop de novo guidelines for CSN members to im-
prove the health of patients with kidney disease in
Canada. High quality CPG development requires consid-
erable resources. While the CSN continues to develop
de novo guidelines, collaboration with, and adaptation
of, guidelines produced by other relevant organizations
including Kidney Disease Improving Global Outcomes
(KDIGO), has also been identified as a priority by the
CSN membership. To this end the CPG committee has
developed principles and a process for the two main ac-
tivities of the Committee: 1) the development of de novo
guidelines, and 2) the adaptation of existing guidelines
through a review and written commentary.The CPG Committee is guided by Terms of Reference
that outline roles and responsibilities of the Chair and
Members. The Chair is appointed by the CSN President
for a 4-year term, and also serves as a member of the
CSN Council. Consideration for the CPG committee com-
position includes representation from other relevant CSN
subcommittees, representatives from pediatrics, trans-
plantation and those with expertise in guideline develop-
ment. As the provision of renal health care services occurs
at the provincial level, and in some instances the regional
level, consideration of geographic representation on the
CPG Committee as well as workgroups in charge of devel-
oping de novo CPG and commentaries is also important.
All members are required to disclose potential conflicts of
interest, including members involved in the working
groups for developing de novo CPGs as well as commen-
taries on existing guidelines. The conflict of interest dis-
closures are published along with the manuscripts.
In this review we describe the CSN process of adapting
existing CPG and developing accompanying commentar-
ies, and document the CSN process and experience of
creating de novo CPG using the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
approach [3].
Review
Prioritizing topics for guideline development – response
from the nephrology community
Surveys of the CSN membership (approximately 460 in-
dividuals) were undertaken in 2009 and 2013 to get
members’ input on the need for guidelines to be pro-
duced by the CSN, and the focus of future guidelines.
The survey was sent via email to members using Fuild-
surveys, and included a combination of multiple choice
and open ended questions. In the 2009 survey, 84% of re-
spondents felt that the CSN should continue to produce
guidelines, with the majority (72%) indicating that the
Mustafa et al. Canadian Journal of Kidney Health and Disease 2014, 1:5 Page 3 of 7
http://www.cjkhd.org/content/1/1/5CSN should not duplicate guidelines produced by other
organizations such as KDIGO. A CPG for the manage-
ment of intensive hemodialysis was identified as a priority
topic area with the 2009 survey, and has since been com-
pleted [4]. The 2013 survey also elicited membership pri-
ority for future guideline development, with the following
three top ranked topics: Management of failing kidney
transplant patients transitioning to dialysis; management
of central venous catheters in hemodialysis, and monitor-
ing and maintenance of arterio-venous access patency.
Based on the results of this survey, and consensus from
the CPG Committee, the next CSN CPG topic to be pro-
duced will be “Management of failing kidney transplant
patients transitioning to dialysis”. Although there are limi-
tations to the use of these survey methods to elicit prior-
ities for guideline topics, we did obtain a high response
rate and obtained input from across Canada. The CSN
CPG Committee will continue to obtain input from the
Canadian nephrology community in the future to pri-
oritize guideline development.
Factors considered when developing or commenting on
recommendations
In general the CSN CPGs and Commentaries focus on
the effect of an intervention (treatment, performing tests
or management strategy) on clinical outcomes that are
important to patients (e.g. survival, quality of life, major
bleeding) and not on surrogate outcomes (e.g. change in
laboratory value or radiologic finding). The CSN CPG
developers and Commentary writers are cautious not to
draw strong conclusions if an intervention has not been
shown to influence important patient outcomes. Since
the CSN has adopted the GRADE process its CPGs and
Commentaries have been guided by a systematic and
transparent “Evidence-to-Recommendations” framework;
that includes the following factors: 1) emphasis on avail-
able evidence and its quality; 2) balance of benefits and
harms; 3) patients’ and societies’ values and preferences
and 4) resource implications and feasibility consider-
ations. The quality of the body of evidence is an import-
ant consideration as it refers to the confidence guideline
developers can place in the available evidence. In other
words, the guideline panel confidence that an additional
body of evidence addressing the same question is un-
likely to change what we already know. Patients’ and so-
cieties’ values and preferences are another critical factor
that is considered in CSN CPGs and commentaries, with
a focus on the specific values in the Canadian context.
Where possible resource, feasibility, and cost consider-
ations (from a Canadian perspective), are included, such
as the use of Canadian micro-costing data to show re-
source implications of a recommendation in the Canad-
ian healthcare setting (CSN timing the initiation of
chronic dialysis CPG [5]).The CSN experience developing clinical practice guidelines
The CSN has developed multiple CPGs since it was
established. The CSN process to develop CPGs since
adopting GRADE include the following steps:
 Priority setting to determine CPG topics.
 Choose CPG chair/s and establish the working
group with representatives from different specialties
(e.g. adult and pediatric nephrologists, primary care
providers and family physicians, endocrinologists
etc.), allied health (e.g. pharmacists, nurses,
dietitians etc.), different practice settings (e.g.
academic, community, rural etc.) and different
geographical and provincial areas. Methodological
and guideline development expertise are also
considerations when composing CPG working
groups.
 Establish CPG development processes and means of
communications with clear deadlines for each step.
 Identify target audience and specific topics selection
including a focus on treatment vs. diagnosis or a
specific population
 Involve end users and stakeholders. This has
become a focus for the CSN to ensure CPGs meet
the needs of users by developing productive and
effective partnerships.
 Generate and select specific answerable questions
using PICO format (Patient, intervention,
comparison and Outcomes) when appropriate.
 Select outcomes and intervention that are important
to patients.
 Conduct a systematic search for relevant evidence
including registries of trials and contacting authors
of unpublished results that may inform the
guidelines.
 Summarize the body of evidence and generate
additional information. For example, in the intensive
hemodialysis CPG, we surveyed programs to
systematically collect information about their
experience with the use of “closed connector”
devices in patients using a central venous catheter as
their access due to paucity of published data.
Summarizing the evidence is done using GRADE
summary tables (GRADE Evidence Profiles) that can
be produced using the Guideline Development Tool
[6] (http://www.guidelinedevelopment.org) (formerly
called GRADEpro).
 Critically appraise the evidence and its quality,
strength or certainty.
 Develop recommendations and determine their
strengths. Developing recommendations involves the
use of a structured framework that ensures a
transparent and systematic process. In GRADE
there are two strengths of recommendations; strong
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for or against the intervention under question and
can be a strong or weak/conditional
recommendation. Determining the strength of the
recommendations refers to judgments about how
confident a guideline panel is that the
implementation of a recommendation exerts more
desirable than undesirable consequences. Table 1
summarises the implications of the different
strengths of recommendations to different end
users.
 Finalize wording of recommendations and the
remarks/explanations that are required to clarify
issues for end-users.
 Peer review. Similar to the CSN commentaries,
external peer review with up to three experts in the
field is conducted, with revisions as required.
 Disseminating, implementing and evaluating the
effects of the CPG. Details about this are described
in a later section in this review.
 Update - a clear plan for updating is outlined in each
CPG.
CSN adheres to international standards in guideline
development methods including the AGREE tool and
the Institute of Medicine trustworthy guidelines stan-
dards [7,8]. CSN methods are also in line with a recent
publication by leaders in the GRADE working group
summarizing a comprehensive checklist for a successful
guideline enterprise [9].
The CSN process for adapting existing clinical practice
guidelines
Multiple international organizations develop nephrology
guidelines. For example, KDIGO is a global guideline
organization, with a goal to develop guidelines in every
major area of kidney disease [10], from an international
perspective. Since its inception in 2003, KDIGO has
completed nine comprehensive guidelines. Given the
time and resources required in rigorous guideline devel-
opment, the CSN CPG has focused on collaboration
with and adaptation of existing international guidelines
like KDIGO, to avoid duplication in effort and to
consolidate guideline development. An overview of theTable 1 Implications to strong and weak/conditional recomm
End-Users Strong recommendations
Patients Most people in this situation would want the recommen
course of action and only a small proportion would not
Clinicians Most patients should receive the recommended course
of action
Policy makers The recommendation can be adapted as a policy in
most situationsCommentaries published and under development is pro-
vided in Table 2. To maintain methodological rigor, the
CSN CPG subcommittee has developed standards for
adapting existing guidelines. Reviews and written com-
mentaries of existing CPG include the following steps:
 A working group is established consisting of a Chair
and co-Chair, appointed by the CSN CPG Committee.
A multidisciplinary working group is then formed
with invitation to the general CSN membership, as
well as invitations to members with known expertise
and experience in the topic. The composition varies
depending on the guideline, but in general includes
nephrologists (adult and pediatric) with clinical and
content expertise, relevant physician specialty groups
(such as endocrinology, primary care etc.) and
members of the allied health community (pharmacists,
nursing, dieticians etc.), with consideration for
geographical representation across Canada.
 The working group identifies recommendations that
require further exposition. Examples of the
recommendation that are relevant for interpretation
and application may include “challenging” the
evidence on which recommendations are based,
consideration of resource constraints (frequently
excluded from guideline development), and
consideration of factors specific to funding and
delivery of health care in Canada. A discussion of
the “Implications for Canadian Health Care” is
created for each identified recommendation.
Additionally, recommendations that can be the basis
for targeted knowledge translation activities relevant
to the local, regional and national context are
highlighted.
 Existing guidelines are assessed using the Appraisal
of Guidelines Research and Evaluation (AGREE II)
[7] instrument as a framework for assessing their
quality. Where applicable, guidelines produced by
KDIGO may also undergo the application of the
ADAPTE process [18], which further considers
cultural and organizational contexts. Adaptation of
international guidelines considers key questions
including variation in: need (prevalence, baseline
risk or pre-test probability of health status);endations to different end-users
Weak/Conditional recommendations
ded The majority of people in this situation would want the
recommended course of action, but many would not
Be more prepared to help patients to make a decision that is
consistent with their own values/decision aids and shared
decision making
There is a need for substantial debate and involvement
of stakeholders
Table 2 Canadian society of nephrology commentaries on kdigo clinical practice guidelines
Date (Ref) Commentary Status
AJKD 2010 [11] Canadian Society of Transplantation and Canadian Society of Nephrology on the 2009 KDIGO
Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Published
AJKD 2010 [12] Canadian Society of Nephrology Commentary on the 2009 KDIGO Clinical Practice Guideline
for the Diagnosis, Evaluation and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD)
Published
AJKD 2013 [13] Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline
for Acute Kidney Injury
Published
AJKD 2013 [14] Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for
Anemia in CKD
Published
AJKD 2014 [15] Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice
Guideline for Management of BP in Chronic Kidney Disease
In press
AJKD 2014 [16] Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guidelines
for Glomerulonephritis: Management of Glomerulonephritis in Adults
In press
AJKD 2014 [17] Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guidelines for
Glomerulonephritis: Management of Nephrotic Syndrome in Children
In press
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availability of resources and variability in costs; and
relative values that patients and societies place on
the main benefits and downsides that might lead to
different decisions.
 The CSN CPG arranges peer review of the
commentary with up to three experts in the field,
following which the working group undertakes
revisions based on reviewer comments.
 Dissemination and implementation of the
Commentaries are as outlined in a later section,
including publication in a nephrology journal.
Developing recommendations and applying grade when
evidence quality (confidence in the effect estimates) is low
Some may argue that in certain situations CPGs should
not be developed either due to the lack of high quality
evidence, or even when high quality evidence exists,
when there is close balance between benefits and harms
and lack of clear evidence about patients’ values in rela-
tions to these benefits or harms. Although guidance is
typically more needed when evidence is of low quality,
some are concerned that developing recommendations
may be misconceived as indorsing this low quality evi-
dence. Hence, outlining the quality of evidence when it
is poor is crucial to prevent the promotion of false confi-
dence regarding the best management strategies.
It is generally well recognized that nephrology lags be-
hind other medical sub-specialties in the availability of
clinical trials to inform decision making, and hence
guidelines. The use of the GRADE process is particularly
beneficial in this regard, given the transparency of the
process and summary of available evidence. It was clear
that reviewers of the CSN CPGs appreciated this trans-
parency and found particular value in the “Evidence-to-
Recommendation” tables. In addition to summarizing
the evidence, these evidence summaries highlight theshortcomings of the evidence, emphasize the knowledge
gaps and identify priorities for future research. There is
an emphasis not only on identifying knowledge gaps of
the effects of specific interventions but also regarding
unknown patients’ values and preferences, physicians’
perceptions, and feasibility and resources consideration.
Additionally, comprehensive evidence review and consen-
sus regarding the recommendations promoted valuable
new research collaborations to conceive new studies, and
strengthened the position of different groups in applying
for funding opportunities to support these new studies.
An example of an evidence-to-recommendations table is
published as a supplementary material of the CSN inten-
sive hemodialysis and timing the initiation of dialysis
guidelines [4,5].
Challenges faced and suggested solutions
There remain challenges in applying a transparent and
rigorous process such as GRADE. These challenges in-
clude need for: 1) resources, and in particular those
needed to conduct well done systematic reviews, 2)
methodological expertise to synthesize the body of evi-
dence and summarize it including experience with ap-
praising and summarizing evidence across different
study design, 3) experience in the process used to de-
velop the CPGs such as GRADE, 4) training of the
guideline panels to explain the process, 5) communica-
tion of the process between clinical and methodological
experts to identify and critically appraise the body of the
evidence.
The CSN has realized the importance of addressing
these challenges by: 1) providing funds to facilitate con-
ducting comprehensive high quality systematic reviews.
A process that proved beneficial for the development of
CPG despite the limited amount of this funding. The by-
product of this process is the opportunity for the guide-
line panels to coauthor high impact publications and
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itional professional and intellectual incentive and facili-
tates academic advancement, 2) encouraging the guideline
groups to focus the scope of the CPG and maintain the
rigor rather than attempting to address a wide range of
clinical questions without the availability of the needed re-
sources including panel members time, 3) providing
GRADE training to the CSN CPG committee members,
panels of different CPG, and members of the CSN utiliz-
ing a variety of options including online webinars and in
person workshops, 4) ensuring that each guideline work-
ing group has clinical and methodological experts, 5) in-
cluding less experienced panel members in each working
group to guide them into the process, 6) facilitating good
communication among panel members along the process
of developing CPGs including supporting conference calls
and in person meetings at national and international
nephrology conferences including the CSN annual meet-
ing, 7) reviewing the process after the guideline has been
published to identify areas that can be modified in future
guideline development. The CSN remains open to incorp-
orate new methodological advances in the area of CPGs
development and to help its members keep up to date.
Dissemination, implementation and evaluation of the
effect of CSN guidelines and commentaries
An active implementation process is required to ensure
uptake of guidelines and commentaries. Dissemination
of the CSN CPG and Commentaries is done through a
variety of approaches including publication in peer-
reviewed nephrology journals, posting of the full docu-
ments on the CSN website with relevant links, posting
of summaries and links to other nephrology guideline
sites and presentation of the CPG and commentaries in
appropriate local, national and international forums. The
CSN CPG also partners with the Canadian Kidney Know-
ledge Translation and Generation Network (CANN-NET)
[19], a national organization aimed to improve care for
patients with and at risk for chronic kidney disease.
CANN-NET plays an active role in the dissemination
and implementation of CSN CPG and Commentaries
through their links with relevant knowledge users and
targeted activities to improve knowledge uptake and
dissemination.
The CSN CPGs are viewed favorably internationally
due to the rigor, transparency and focused scope. Re-
cently the Saudi Ministry of Health adapted the CSN
CPG on timing the initiation of chronic dialysis. The evi-
dence tables summarizing available evidence and dis-
cussing its strength simplified the adaptation process.
Additionally, the “evidence-to-recommendations” frame-
work facilitated incorporation of local values, preferences
and resources that are unique to the Saudi context. We an-
ticipate that use of GRADE will allow other internationalgroups to easily adopt or adapt the CSN recommendations
and further facilitates their dissemination.
In addition to dissemination and implementation,
evaluation of the impact of the guidelines and commen-
taries on physician practice and patient outcomes is also
a CSN priority. In the past, a formal evaluation of the ef-
fect of the guidelines and commentaries on practice
change has not been undertaken. However through
CANN-NET, and with the availability of data from the
Canadian Organ Replacement Registry (CORR), the ef-
fectiveness of these knowledge translation activities on
process of care and clinical outcomes can be tracked.
Canada is fortunate to having universal healthcare with
fairly robust health services data at provincial and na-
tional level.
Conclusion
The CSN follows a comprehensive process in developing
de novo CPGs and writing Commentaries. In 2010, the
CSN adopted GRADE, which enhanced the rigor and
transparency of guideline development. This process fo-
cuses on systematically identifying all available evidence
and carefully assessing its quality, balancing all import-
ant patient outcomes including benefits and harms, con-
sidering patients’ and societies’ values and preferences,
and when possible considering feasibility and resource
implications. The CSN also follows a comprehensive and
transparent process in identifying priority areas to be ad-
dressed in CPGs. This process includes surveying its
members and its collaborators’ members to address
questions that are of relevance to the national nephrol-
ogy community. Some of these questions have been
identified as priority questions in other countries and
led to adaptation of the CSN CPG internationally. One
very interesting development is the creation of new part-
nerships allowing wider dissemination and implementa-
tion among end users. Moreover, these partnerships
permit evaluating the effects of different knowledge trans-
lation products like CPG and commentaries on the health
of Canadians. Following this process clearly addresses the
CSN mission of promoting the highest quality of care for
patients with kidney disease and encouraging research re-
lated to the kidney and its disorders.
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